Lunit KRX:328130, a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer SITC 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunits AI-powered digital pathology technologies-Lunit SCOPE IO and Lunit SCOPE uIHC-can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development.
Lunit and CellCarta presented a comparative analysis demonstrating that AI can standardize tumor immune phenotyping across multiple cancer types, including non-small cell lung, colorectal, and urothelial cancers. When assessing tumor and stromal segmentation, Lunit SCOPE IO showed high concordance with pathologist assessments based on traditional immunohistochemistry Spearmans correlation coefficients of 0.91 and 0.86. Threshold calibration improved alignment between the AI-based and pathologist scoring of inflamed, excluded, and desert immune phenotypes and improved its reliability and reproducibility. These results position Lunit SCOPE IO as a scalable solution for immune profiling, reducing reliance on additional IHC staining and enabling consistent analysis of the tumor immune microenvironment in both research and clinical practice.
Lunit also introduced new data showcasing the utility of Lunit SCOPE uIHC, the companys AI-powered quantitative IHC platform, in mapping spatial interactions between tumor-infiltrating lymphocytes TILs and 74 membrane-specific protein targets currently in development for antibody-based therapies such as antibody-drug conjugates ADCs and bispecific T-cell engagers BiTEs. Analyzing over 47,000 IHC images across 34 cancer types, the study revealed that while most protein targets showed decreased TIL density within expression regions, select proteins such as PD-L1 and TNFRSF4, displayed positive spatial correlation with lymphocyte infiltration. Notably, FGFR4 expression was linked to increased intra-tumoral lymphocytes in colorectal, non-squamous lung, and uterine cancers, suggesting its potential as a BiTE target. The findings demonstrate how Lunit SCOPE uIHC can integrate spatial immune context into early drug discovery workflows, accelerating the identification and validation of therapeutic targets.